Kymera Therapeutics Q1 2026 earnings snapshot

Kymera Therapeutics (KYMR) has kicked off Q1 2026 with the market watching closely after recent quarters that paired modest revenue with sizeable losses, including Q4 2025 revenue of US$2.9 million and a basic EPS loss of US$0.97 on net income excluding extra items of a US$87 million loss. Over the past year, the company has seen quarterly revenue range from US$2.8 million to US$22.1 million, while basic EPS losses moved between US$0.82 and US$0.97 per quarter as trailing twelve month earnings excluding extra items totaled a US$311 million loss on revenue of US$39.2 million. With analysts still focused on revenue growth expectations and a mixed risk reward profile, this set of results keeps attention on how efficiently Kymera converts any future top line gains into improving margins.

See our full analysis for Kymera Therapeutics.

With the headline numbers set, the next step is to see how Kymera's latest margins and growth profile line up against the widely followed bullish and cautious narratives around the stock.

Losses deepen on a trailing US$311 million basis

• Over the last twelve months, Kymera reported a net loss excluding extra items of US$311.4 million on revenue of US$39.2 million, which means expenses remain far above the top line on a trailing basis.
• Consensus narrative points out that high R&D spending is central to the story, and the recent quarterly net losses between US$62.5 million and US$87.0 million line up with that. Forecasts for earnings to decline about 0.4% per year over the next three years keep the focus on how long this phase of heavy investment can continue without pressuring long term financial health.
  • Critics highlight that Kymera is unprofitable today and is not expected to reach profitability within the next three years even as revenue is forecast to grow about 45.3% per year.
  • The widening multi year loss trend of about 27.5% per year adds weight to concerns that earnings may not quickly follow any revenue gains.

Revenue forecasts at 45.3% growth face flat recent sales

• Analysts expect revenue to grow about 45.3% per year. However, the last four reported quarters show revenue in a relatively narrow band from US$2.8 million to US$22.1 million, with the latest two quarters at US$2.9 million and US$2.8 million, so the current reported top line is still modest compared with the growth outlook.
• Bulls argue that advancing programs and collaborations could support higher revenue over time, and the forecast growth rate well above the roughly 11% US market expectation reflects that optimism. The recent trailing twelve month revenue of US$39.2 million and basic EPS losses between US$0.82 and US$0.97 per quarter underline how much of that bullish view is still based on future execution rather than current sales.
  • Consensus commentary points to planned Phase II and III trials and multiple clinical programs as reasons revenue could eventually scale beyond the recent quarterly range.
  • At the same time, forecasts that earnings will decline modestly over the next three years show that even with this projected revenue growth, profitability is not expected to turn positive soon.

On these numbers, bulls are effectively betting that strong forecast revenue growth will eventually balance out years of heavy losses and high R&D before the current cash runway runs its course, so it is worth seeing how that optimistic case is laid out in detail. 🐂 Kymera Therapeutics Bull Case

Mixed valuation: 4.2x P/B with 46.6% implied upside

• Kymera trades at a P/B of 4.2x, above the wider US biotech industry average of 2.2x but below the peer average of 7.2x, while analysts’ consensus price targets imply about 46.6% upside from the current share price of US$81.07 to US$118.86.
• Bears argue that paying above industry book multiples for a company with forecast earnings declines and no path to profitability in the next three years is a stretch. The fact that shareholders have already experienced dilution plus recent insider selling, together with a trailing US$311.4 million loss, gives that cautious view some backing even though the implied upside from analyst targets signals that many forecasts still expect stronger long term value creation than the current P/B alone might suggest.
  • Risk analysis highlighting ongoing dilution and insider selling directly challenges the idea that the recent valuation is purely a bargain based on book value.
  • At the same time, analyst targets that sit above today’s US$81.07 share price suggest that some expect future developments to justify P/B levels closer to or above peers despite current losses.

Given these tensions between valuation, losses and forecasts, some investors will want to stress test the more cautious case before deciding how much weight to give the recent P/B and target price signals. 🐻 Kymera Therapeutics Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Kymera Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and concern feels familiar, that is the point. You should move quickly to review the 2 key rewards and 4 important warning signs 2 key rewards and 4 important warning signs

See What Else Is Out There

Kymera is running heavy losses against modest revenue, with no near term path to profitability and risks tied to dilution, insider selling, and valuation.

If that mix of high risk and uncertainty feels a bit too intense, it makes sense to compare with companies screened for 74 resilient stocks with low risk scores right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.